R&D channel feed – Endpoints News

R&D channel feed

Takeda takes $140M hit on Phase 3 epilepsy flop, previews late-stage trials for pipeline prospects

10 months ago

Umoja to dose first patient with in vivo CAR-T by end of this year

10 months ago

Exclusive: Myeloid Therapeutics moves second in vivo cell therapy into trials, targeting liver cancer

10 months ago

FibroGen to shrink US workforce by 75% following more late-stage fails

10 months ago

Incyte drops four early-stage programs from its pipeline as part of strategic review

10 months ago

Imunon shares up over 150% as ovarian cancer treatment extends survival in Phase 2

10 months ago

BioNTech, Regeneron claim Phase 2 win for cancer vaccine, PD-1 combo

10 months ago

Celldex says antibody drug improves irritable skin condition in Phase 2 test

10 months ago

Roche begins Phase 2 obesity trial for GLP-1/GIP agonist, striking while iron is hot

10 months ago

Ventyx axes development of TYK2 inhibitor following Phase 2 failure

10 months ago

Cognition Therapeutics' stock sinks on Phase 2 Alzheimer’s data

10 months ago

NewAmsterdam succeeds in the first of three key pivotal studies, providing hope to a troubled cardio class

10 months ago

AstraZeneca’s fixed-duration Calquence combo succeeds in Phase 3 blood cancer test

10 months ago

vTv Therapeutics' diabetes drug program hit with clinical hold from FDA

10 months ago

Anavex’s new analysis of its Alzheimer’s pill shows mixed results

10 months ago

Updated: Bristol Myers restarts radiopharmaceutical Phase 3 trial

10 months ago

Cue Biopharma prioritizes autoimmune pipeline, axes a quarter of staff to save cash

10 months ago

Calliditas claims mid-stage win for rare liver disease drug

10 months ago

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

10 months ago

FDA advisors call for better studies of immunotherapy around lung cancer surgery, but give AstraZeneca a pass

10 months ago

Sanofi shelves four assets, including mid-stage dwarfism candidate

10 months ago

AbbVie expects $8.7B Cerevel buy to close ‘as early as next week,’ new CEO says

10 months ago

Roche cuts two more TIGIT trials, plans accelerated timeline for obesity drugs

10 months ago

Argenx to retest Vyvgart in autoimmune platelet disease after failure last year

10 months ago

First page Previous page 34 35 363738 39 40 Next page Last page